CML patients with low levels of CD62L on T lymphocytes and high levels of soluble CD62L in plasma induce a pro-inflammatory leukemic environment, while nilotinib increases CD62L expression on T lymphocytes and thus improves antitumor immunity [114]. Here, SELL is linked to chronic myelogenous leukemia, BCR-ABL1 positive.